Cargando…

Expanding the Reach of Precision Oncology by Drugging All KRAS Mutants

KRAS is the most frequently mutated oncogene, harboring mutations in approximately one in seven cancers. Allele-specific KRAS(G12C) inhibitors are currently changing the treatment paradigm for patients with KRAS(G12C)-mutated non–small cell lung cancer and colorectal cancer. The success of addressin...

Descripción completa

Detalles Bibliográficos
Autores principales:	Hofmann, Marco H., Gerlach, Daniel, Misale, Sandra, Petronczki, Mark, Kraut, Norbert
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	American Association for Cancer Research 2022
Materias:	Reviews
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9394389/ https://www.ncbi.nlm.nih.gov/pubmed/35046095 http://dx.doi.org/10.1158/2159-8290.CD-21-1331

Ejemplares similares

Combined KRAS(G12C) and SOS1 inhibition enhances and extends the anti-tumor response in KRAS(G12C)-driven cancers by addressing intrinsic and acquired resistance
por: Thatikonda, Venu, et al.
Publicado: (2023)

Radiomics in precision oncology: hype or ludum mutante
por: Tay, Shi Hui, et al.
Publicado: (2023)

Kinetochores expand their reach
por: Short, Ben
Publicado: (2015)

Exploiting macropinocytosis for drug delivery into KRAS mutant cancer
por: Liu, Huiqin, et al.
Publicado: (2022)

Escaping KRAS: Gaining Autonomy and Resistance to KRAS Inhibition in KRAS Mutant Cancers
por: Adachi, Yuta, et al.
Publicado: (2021)

Restoring PUMA induction overcomes KRAS-mediated resistance to anti-EGFR antibodies in colorectal cancer
por: Knickelbein, Kyle, et al.
Publicado: (2018)

Small Molecule KRAS Agonist for Mutant KRAS Cancer Therapy
por: Xu, Ke, et al.
Publicado: (2019)

Expanding the role of interventional oncology for advancing precision immunotherapy of solid tumors
por: Kimura, Yasushi, et al.
Publicado: (2021)

Sequence Alignment Tools: One Parallel Pattern to Rule Them All?
por: Misale, Claudia, et al.
Publicado: (2014)

Targeting KRAS mutant cancers: from druggable therapy to drug resistance
por: Zhu, Chunxiao, et al.
Publicado: (2022)

A combination therapy for KRAS-mutant lung cancer by targeting synthetic lethal partners of mutant KRAS
por: Pang, Xiufeng, et al.
Publicado: (2016)

Expanding the Reach of Pediatric Transcatheter Pacing
Publicado: (2021)

Correction to: Small Molecule KRAS Agonist for Mutant KRAS Cancer Therapy
por: Xu, Ke, et al.
Publicado: (2020)

Defeat mutant KRAS with synthetic lethality
por: Pang, Xiufeng, et al.
Publicado: (2016)

Peri-hand space expands beyond reach in the context of walk-and-reach movements
por: Berger, Michael, et al.
Publicado: (2019)

A potent KRAS macromolecule degrader specifically targeting tumours with mutant KRAS
por: Bery, Nicolas, et al.
Publicado: (2020)

Expanding Physics Reach with Unused Tracks in LHCb
por: Sanderswood, Izaac
Publicado: (2022)

Shifting, overlapping and expanding use of “precision oncology” terminology: a retrospective literature analysis
por: Tran, Audrey, et al.
Publicado: (2020)

KRAS mutant colorectal tumors: Past and present
por: Brand, Toni M., et al.
Publicado: (2012)

Distinct metabolic preference of atypical KRAS mutant
por: Cheong, Heesun
Publicado: (2020)

Current therapy of KRAS-mutant lung cancer
por: Ghimessy, Aron, et al.
Publicado: (2020)

Small molecular inhibitors for KRAS-mutant cancers
por: Wu, Xuan, et al.
Publicado: (2023)

Suppression of KRas-mutant cancer through the combined inhibition of KRAS with PLK1 and ROCK
por: Wang, Jieqiong, et al.
Publicado: (2016)

Wild-Type KRAS Allele Effects on Druggable Targets in KRAS Mutant Lung Adenocarcinomas
por: Baldelli, Elisa, et al.
Publicado: (2021)

Precise and efficient silencing of mutant Kras(G12D) by CRISPR-CasRx controls pancreatic cancer progression
por: Jiang, Wang, et al.
Publicado: (2020)

Selective targeting of KRAS-Mutant cells by miR-126 through repression of multiple genes essential for the survival of KRAS-Mutant cells
por: Hara, Toshifumi, et al.
Publicado: (2014)

IPTV and Internet video: expanding the reach of television broadcasting
por: Simpson, Wes, et al.
Publicado: (2007)

IPTV and internet video: expanding the reach of television broadcasting
por: Simpson, Wes, et al.
Publicado: (2009)

Telehealth for Expanding the Reach of Early Autism Training to Parents
por: Vismara, Laurie A., et al.
Publicado: (2012)

Expanding the reach of respiratory therapy: A need for evaluation
por: Nickerson, Jason
Publicado: (2015)

Pharmacy delivery to expand the reach of PrEP in Africa
por: Ortblad, Katrina F, et al.
Publicado: (2020)

Expanding JNO offerings and their reach with “Tumor Talk” webinars
por: D’Amico, Randy, et al.
Publicado: (2023)

MUC1-C confers EMT and KRAS independence in mutant KRAS lung cancer cells
por: Kharbanda, Akriti, et al.
Publicado: (2014)

Periodontal microsurgery: Reaching new heights of precision
por: Yadav, Vikender Singh, et al.
Publicado: (2018)

An appraisal of drug development timelines in the Era of precision oncology
por: Jardim, Denis Leonardo, et al.
Publicado: (2016)

“Hard” Drug Repurposing for Precision Oncology: The Missing Link?
por: Pantziarka, Pan, et al.
Publicado: (2018)

Expanding the Reach of Monoclonal Antibodies: A Review of Synthetic Nucleic Acid Delivery in Immunotherapy
por: Chung, Christopher, et al.
Publicado: (2023)

Dasatinib sensitizes KRAS mutant colorectal tumors to cetuximab
por: Dunn, Emily F., et al.
Publicado: (2010)

Acquired palbociclib resistance in KRAS-mutant lung cancer
por: Sherr, Charles J.
Publicado: (2018)

Mutant KRAS promotes malignant pleural effusion formation
por: Αgalioti, Theodora, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_qnnt5eflg5hj0n6ns6mh3kk3rh